Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 22-Nov-24 6:25 PM View:  | Michor Franziska Director | Recursion Pharmaceuticals, ... (RXRX) | 20-Nov-24 | Grant | 105,037 | -- | -- | 100% 0 to 105.04K | |
| 19-Nov-24 6:26 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 15-Nov-24 | Payment of Exercise | 26,023 | $6.18 | $160,692.00 | (3%) 762.66K to 736.63K | |
| 19-Nov-24 6:26 PM View: | Mauro David J Chief Medical Officer | Recursion Pharmaceuticals, ... (RXRX) | 15-Nov-24 | Payment of Exercise | 4,187 | $6.18 | $25,854.70 | (2%) 229.62K to 225.43K | |
| 19-Nov-24 6:26 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 15-Nov-24 | Payment of Exercise | 11,937 | $6.18 | $73,711.00 | (< 1%) 1.5M to 1.49M | |
| 19-Nov-24 6:26 PM View: | Larson Tina Marriott President and COO | Recursion Pharmaceuticals, ... (RXRX) | 15-Nov-24 | Payment of Exercise | 14,286 | $6.18 | $88,216.10 | (3%) 521.14K to 506.85K | |
| 15-Nov-24 6:52 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 14-Nov-24 | Conversion | 20,000 | -- | -- | 3% 762.66K to 782.66K | |
| 15-Nov-24 6:52 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 14-Nov-24 | Sale (Planned) | 20,000 | $7.35 | $147,000.00 | (3%) 782.66K to 762.66K | |
| 14-Nov-24 7:19 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 13-Nov-24 | Option Exercise | 39,375 | $2.22 | $87,412.50 | 3% 1.48M to 1.51M | |
| 15-Nov-24 6:52 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 13-Nov-24 | Conversion | 20,000 | -- | -- | 3% 762.66K to 782.66K | |
| 15-Nov-24 6:52 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 13-Nov-24 | Sale (Planned) | 20,000 | $7.74 | $154,800.00 | (3%) 782.66K to 762.66K | |
| 14-Nov-24 7:19 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 13-Nov-24 | Planned Option Sale | 15,000 | $7.66 | $114,876.00 | (< 1%) 1.51M to 1.5M | |
| 14-Nov-24 7:19 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 12-Nov-24 | Planned Option Sale | 15,000 | $7.64 | $114,628.00 | (1%) 1.49M to 1.48M | |
| 14-Nov-24 7:19 PM View: | Borgeson Blake Director | Recursion Pharmaceuticals, ... (RXRX) | 12-Nov-24 | Sale (Planned) | 11,447 | $7.64 | $87,457.40 | (< 1%) 7.08M to 7.07M | |
| 14-Nov-24 7:19 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 12-Nov-24 | Option Exercise | 39,375 | $2.22 | $87,412.50 | 3% 1.45M to 1.49M | |
| 10-Oct-24 6:40 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 09-Oct-24 | Planned Option Sale | 15,000 | $6.36 | $95,374.50 | (1%) 1.47M to 1.45M | |
| 10-Oct-24 6:40 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 09-Oct-24 | Option Exercise | 39,375 | $2.22 | $87,412.50 | 3% 1.43M to 1.47M | |
| 10-Oct-24 6:40 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 08-Oct-24 | Option Exercise | 39,375 | $2.22 | $87,412.50 | 3% 1.4M to 1.44M | |
| 10-Oct-24 6:40 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 08-Oct-24 | Planned Option Sale | 15,000 | $6.32 | $94,756.50 | (1%) 1.44M to 1.43M | |
| 04-Oct-24 6:30 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 03-Oct-24 | Sale (Planned) | 20,000 | $6.08 | $121,600.00 | (3%) 782.66K to 762.66K | |
| 04-Oct-24 6:30 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 03-Oct-24 | Conversion | 20,000 | -- | -- | 3% 762.66K to 782.66K | |
| 04-Oct-24 6:30 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 02-Oct-24 | Sale (Planned) | 20,000 | $6.16 | $123,200.00 | (3%) 782.66K to 762.66K | |
| 04-Oct-24 6:30 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 02-Oct-24 | Conversion | 20,000 | -- | -- | 3% 762.66K to 782.66K | |
| 04-Oct-24 6:29 PM View: | Li Dean Y Director | Recursion Pharmaceuticals, ... (RXRX) | 01-Oct-24 | Grant | 1,925 | -- | -- | < 1% 3.19M to 3.19M | |
| 04-Oct-24 6:30 PM View: | Dar Zavain Director | Recursion Pharmaceuticals, ... (RXRX) | 01-Oct-24 | Grant | 2,229 | -- | -- | 2% 104.0K to 106.22K | |
| 04-Oct-24 6:30 PM View: | Borgeson Blake Director | Recursion Pharmaceuticals, ... (RXRX) | 01-Oct-24 | Grant | 2,026 | -- | -- | < 1% 7.1M to 7.1M | |
| 30-Sep-24 6:15 PM View: | Larson Tina Marriott President and COO | Recursion Pharmaceuticals, ... (RXRX) | 26-Sep-24 | Planned Option Sale | 6,000 | $7.00 | $42,004.80 | (1%) 527.14K to 521.14K | |
| 30-Sep-24 6:15 PM View: | Larson Tina Marriott President and COO | Recursion Pharmaceuticals, ... (RXRX) | 26-Sep-24 | Option Exercise | 6,000 | $1.06 | $6,360.00 | 1% 521.14K to 527.14K | |
| 19-Sep-24 5:48 PM View: | Borgeson Blake Director | Recursion Pharmaceuticals, ... (RXRX) | 17-Sep-24 | Sale (Planned) | 11,447 | $6.84 | $78,333.00 | (< 1%) 7.12M to 7.11M | |
| 12-Sep-24 6:28 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 11-Sep-24 | Option Exercise | 39,375 | $2.22 | $87,412.50 | 3% 1.38M to 1.42M | |
| 12-Sep-24 6:28 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 11-Sep-24 | Planned Option Sale | 15,000 | $6.32 | $94,729.50 | (1%) 1.42M to 1.4M | |
| 12-Sep-24 6:28 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 10-Sep-24 | Planned Option Sale | 15,000 | $6.17 | $92,499.00 | (1%) 1.39M to 1.38M | |
| 12-Sep-24 6:28 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 10-Sep-24 | Option Exercise | 39,375 | $2.22 | $87,412.50 | 3% 1.35M to 1.39M | |
| 06-Sep-24 4:57 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 05-Sep-24 | Sale (Planned) | 20,000 | $6.14 | $122,800.00 | (3%) 782.66K to 762.66K | |
| 06-Sep-24 4:57 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 05-Sep-24 | Conversion | 20,000 | -- | -- | 3% 762.66K to 782.66K | |
| 06-Sep-24 4:57 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 04-Sep-24 | Conversion | 20,000 | -- | -- | 3% 762.66K to 782.66K | |
| 06-Sep-24 4:57 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 04-Sep-24 | Sale (Planned) | 20,000 | $6.04 | $120,800.00 | (3%) 782.66K to 762.66K | |
| 05-Sep-24 5:25 PM View: | Borgeson Blake Director | Recursion Pharmaceuticals, ... (RXRX) | 03-Sep-24 | Sale (Planned) | 11,447 | $6.27 | $71,717.70 | (< 1%) 7.13M to 7.12M | |
| 03-Sep-24 4:48 PM View: | Larson Tina Marriott President and COO | Recursion Pharmaceuticals, ... (RXRX) | 29-Aug-24 | Planned Option Sale | 6,000 | $7.56 | $45,376.20 | (1%) 527.14K to 521.14K | |
| 03-Sep-24 4:48 PM View: | Larson Tina Marriott President and COO | Recursion Pharmaceuticals, ... (RXRX) | 29-Aug-24 | Option Exercise | 6,000 | $1.06 | $6,360.00 | 1% 521.14K to 527.14K | |
| 29-Aug-24 4:22 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 29-Aug-24 | Option Exercise | 5,000 | $2.48 | $12,400.00 | < 1% 752.66K to 757.66K | |
| 28-Aug-24 10:00 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 28-Aug-24 | Option Exercise | 5,000 | $2.48 | $12,400.00 | < 1% 747.66K to 752.66K | |
| 26-Aug-24 4:42 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 26-Aug-24 | Option Exercise | 5,000 | $2.48 | $12,400.00 | < 1% 737.66K to 742.66K | |
| 23-Aug-24 5:25 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 23-Aug-24 | Option Exercise | 5,000 | $2.48 | $12,400.00 | < 1% 732.66K to 737.66K | |
| 22-Aug-24 6:48 PM View: | Borgeson Blake Director | Recursion Pharmaceuticals, ... (RXRX) | 20-Aug-24 | Sale (Planned) | 11,447 | $7.12 | $81,532.40 | (< 1%) 7.14M to 7.13M | |
| 15-Aug-24 5:24 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 14-Aug-24 | Option Exercise | 39,375 | $2.22 | $87,412.50 | 3% 1.34M to 1.38M | |
| 15-Aug-24 5:24 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 14-Aug-24 | Planned Option Sale | 15,000 | $6.35 | $95,251.50 | (1%) 1.38M to 1.37M | |
| 15-Aug-24 5:24 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 13-Aug-24 | Option Exercise | 39,375 | $2.22 | $87,412.50 | 3% 1.32M to 1.36M | |
| 15-Aug-24 5:24 PM View: | Secora Michael Chief Financial Officer | Recursion Pharmaceuticals, ... (RXRX) | 13-Aug-24 | Planned Option Sale | 15,000 | $6.35 | $95,182.50 | (1%) 1.36M to 1.34M | |
| 09-Aug-24 4:56 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 08-Aug-24 | Conversion | 20,000 | -- | -- | 3% 758.74K to 778.74K | |
| 09-Aug-24 4:56 PM View: | Gibson Christopher Chief Executive Officer Director | Recursion Pharmaceuticals, ... (RXRX) | 08-Aug-24 | Sale (Planned) | 20,000 | $6.50 | $130,000.00 | (3%) 778.74K to 758.74K |
